Abcam, ab258495, Human LDB1 knockout HeLa cell lysate

Size: 1Kit
LDB1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LDB1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LDB1 also known as LIM Domain Binding 1 serves an important role in transcriptional regulation. This protein with a mass of approximately 42 kDa frequently expresses in tissues such as the brain heart and spleen. LDB1 participates in forming multiprotein complexes through its interaction with LIM homeodomain proteins engaging with various co-regulators to influence gene expression.
Biological function summary
LIM Domain Binding 1 plays an important role in developmental processes and cell differentiation. It combines with other proteins to form a LIM complex that acts as a DNA-binding transcriptional regulator. The complex binds to enhancer elements and facilitates the activation or repression of genes critical for the development of the nervous system and cardiovascular system.
Pathways
LIM Domain Binding 1 integrates into the Wnt signaling pathway and the TGF-beta pathway. It interacts with proteins such as TCF/LEF and Smad serving as a cofactor that modulates transcriptional responses and influences cellular outcomes. By participating in these pathways LDB1 helps regulate cell fate decisions ensuring appropriate cellular differentiation and proliferation responses.
LIM Domain Binding 1 holds relevance to leukemia and Wilms' tumor. Its dysregulation connects with disproportionate expression of key developmental genes contributing to pathogenesis. LDB1's interaction with transcription factors like SCL/TAL1 highlights its contribution to the onset of these diseases by modulating gene expression patterns associated with these cancers.